Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Insights - The global interest in China's biopharma sector is driven by the lower costs of early clinical programs compared to the US and Europe, with expectations for increased dealmaking between China and the West as 2026 approaches [1][2] Group 1: Deal Trends and Values - There has been a significant rise in high-value deals between the West and China, with 20 transactions exceeding $500 million in 2023 alone [2] - Major deals in 2025 include Novartis's $5.36 billion agreement with Argo Biopharmaceutical, AstraZeneca's $5.3 billion deal with CSPC Pharmaceutical, and Zenas Biopharma's $2 billion agreement with InnoCare Pharma [2] - Chinese innovator drug licensing deals accounted for 28% of the innovator deals signed by large pharma in 2024, totaling $41.5 billion in value [3] Group 2: R&D and Therapeutic Focus - Western companies are increasingly seeking partnerships with Chinese biotech firms to enhance their pipelines with cost-effective therapies, particularly in oncology, immunology, and cardiometabolic health [4] - The rapid growth of China's clinical trial ecosystem has positioned the country as a leader in global study initiations in 2024 [5] - China is shifting from a reputation for generic drug manufacturing to developing innovative therapies, capturing global pharmaceutical attention [6] Group 3: Oncology and Innovative Therapies - Oncology remains a focal point for licensing agreements, with significant deals from companies like AbbVie, Pfizer, and GSK [9] - Antibody-drug conjugates (ADCs) developed in China are particularly appealing to Western dealmakers due to their innovative potential [10] - Next-generation biologics, including ADCs, bispecifics, and cell and gene therapies, are driving interest from investors and large pharmaceutical companies [11] Group 4: Future Outlook and Strategic Shifts - Immunology is expected to remain a key area of focus in 2026, alongside a rise in cardiometabolic deals targeting the obesity market [13] - The BIOSECURE Act could impact interactions between Western and Chinese companies, but industry leaders express confidence in the resilience of innovation-driven strategies [14][16] - Some Chinese companies are exploring self-commercialization strategies, although most will likely continue to rely on licensing deals in the near term due to a lack of global market experience [18][19]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

Core Insights - Intensity Therapeutics, Inc. is presenting two posters at the San Antonio Breast Cancer Symposium, focusing on its investigational drug INT230-6 for treating Triple Negative Breast Cancer (TNBC) [1][2] Study Observations - The INVINCIBLE-4 study, initiated in 2024, has treated 14 patients, with 7 in each cohort, showing favorable safety data [3][6] - Cohort A (INT230-6 plus standard of care) exhibited 50% fewer grade 3 or higher adverse events compared to Cohort B (standard of care alone) [5][6] - Specific adverse events included 9 grade 3 or higher events in Cohort A versus 20 in Cohort B [6] Clinical Trial Details - The ongoing Phase II randomized clinical trial is evaluating INT230-6's safety and efficacy in early-stage TNBC patients [5][11] - A potential Phase 3 study design may include INT230-6 with standard of care, with and without the anthracycline doxorubicin, aiming for improved safety and efficacy [8][9] Drug Mechanism and Composition - INT230-6 is designed for direct intratumoral injection, combining cisplatin and vinblastine sulfate with a diffusion enhancer to improve drug delivery within tumors [13] - The drug aims to elicit an immune response while minimizing systemic toxicity, a common issue with traditional chemotherapy [13][14] Market Context - TNBC represents a significant challenge in breast cancer treatment, with approximately 56,000 new cases diagnosed annually in the U.S. and 420,000 worldwide [11] - Current standard treatments often involve high toxicity, with 80% of patients experiencing severe adverse events [11] Regulatory Pathway - The FDA's Accelerated Approval Program may facilitate INT230-6's approval based on pathological complete response (pCR) as a surrogate endpoint [12] - If successful, this could lead to a safer treatment regimen for TNBC patients, potentially avoiding the use of highly toxic agents like doxorubicin [11][12]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Group 1 - Proactive Investors provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive has a history of adopting technology to enhance workflows, utilizing decades of expertise among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Company Overview - Amylyx is presenting at the Citi Global Healthcare Conference, highlighting its lead asset, Avexitide, which is in a pivotal study for post-bariatric hypoglycemia (PBH) [3][4] - The company anticipates completion of enrollment for the study in the first quarter and expects top-line results in the third quarter of the year [4] Market Opportunity - PBH affects approximately 160,000 individuals in the U.S., with no approved treatments currently available, indicating a significant unmet medical need [4] - The company is planning for commercialization of Avexitide in 2027 following the study results [4] Future Developments - Amylyx is also exploring a potential long-acting formulation of Avexitide, which would be a daily subcutaneous treatment [4]